OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS
07 December 2019 - 3:45AM
OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN
IN THE FRAME OF REOGANIZATION PROCEEDINGS
COMMUNIQUE DE
PRESSE ·
COMMUNIQUE DE PRESSE
· COMMUNIQUE DE
PRESSE
OPENING OF A CALL FOR TENDER TO PROVIDE A
CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION
PROCEEDINGS
The deadline for submission of all
tenders is January 10th, 2020 before
04:00pm
Paris and Boston, December 6th, 2019 – 05h45pm
CET - Neovacs (Euronext Growth Paris : ALNEV)
announces the launch of a call for tender opened from now until
January 10th, 2020 before 4:00 pm, to provide a continuation plan
through partners or investors (articles L.626-1 and L.626-3 of the
French Commercial code) or a sale plan by one or more buyers
(Articles L.642-1 et seq. of the French Commercial Code).
Candidates are invited to submit their offer
before January 10th, 2020 at 04:00pm at the following law
office: SELARL 2M and associates, to Maître Carole Martinez,
judicial administrator, 22 rue de l'Arcade 75008 Paris, France.
Email: a.dekoninck@aj-2m.com
Access to information for auditing the company
(electronic data room), will be granted upon reasoned written
request to the judicial administrator along with the appropriate
financial, industrial or commercial capacity proofs.
As a reminder, on November 26th, 2019 the
Commercial Court of Paris decided the opening of reorganization
proceedings of the company, as requested by Neovacs (press release
of November 27th, 2019).
Neovacs is a French biotech company listed on
Euronext Growth since 2010. The Company is focused on therapeutic
vaccines targeting the treatment of autoimmune diseases. Its
innovative technology named Kinoid™, patented until 2038, induces a
polyclonal immune response, applicable in several indications.
Neovacs has developed the IFNα KINOID to treat lupus in a clinical
phase IIb study, the main study is now ended and the full results
have been presented at the 13th international Lupus Congress 2019.
The Company also carries out preclinical work on IL-4/ IL-13
Kinoid, another therapeutic vaccine for the treatment of allergies.
The aim of this "KINOID approach" is to enable patients to better
cope with a life-long treatment that would be more effective.
For more information : www.neovacs.fr
Neovacs (EU:ALNEV)
Historical Stock Chart
From Oct 2024 to Nov 2024
Neovacs (EU:ALNEV)
Historical Stock Chart
From Nov 2023 to Nov 2024
